Beam Therapeutics Inc. (BEAM): M&A transaction — Beam Therapeutics nets $255.1M cash from sale of Orbital stake in BMS acquisition

Beam Therapeutics Inc.

Beam received $255.1M in closing cash plus up to ~$26.3M from escrow for its 75M shares (17% fully diluted) of Orbital.
Bristol-Myers Squibb completed acquisition of Orbital on December 8, 2025, triggering the payout.
Beam to update cash runway guidance at the 2026 J.P. Morgan Healthcare Conference.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Beam Therapeutics Inc. completed a disposition involving Bristol-Myers Squibb Company for $255.1 million in closing cash consideration, plus the right to receive up to approximately $26.3 million in additional cash consideration (closed 2025-12-08).

Action: disposition
Counterparty: Bristol-Myers Squibb Company
Consideration: $255.1 million in closing cash consideration, plus the right to receive up to approximately $26.3 million in additional cash consideration
Closing: 2025-12-08

Exact text from the filing

of Orbital common stock, which represented a fully diluted ownership stake of approximately 17%. At the closing of the Acquisition, such shares were cancelled and converted into $255.1 million in closing cash consideration, plus the right to receive up to approximately $26.3 million in additional cash consideration upon the release, if any, of certain escrows. The

View on SEC.gov

Browse all m&a transactions →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-316043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.